TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Antiviral effects of PPI-461
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PPI-461 pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Aspergillus-specific IgG, IgM and IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative number of new gadolinium enhancing lesions on brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiopulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Elbow extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood oxygenation level dependent (BOLD) signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMSE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent improvement in the 6 minute walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in functional magnetic resonance imaging (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in memory and language measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of systemic or cutaneous malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alcohol Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of first relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hydromorphone Use/24 Hours postOP in mg/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehospitalization due to heart failure decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of LPP Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Lanadelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of Lanadelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) in Plasma of Lanadelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Severe Common Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Development of metachronous contralateral inguinal hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Oncological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intradialytic sodium gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter-related bloodstream infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Survival of the implants
Endpoint domain: Mortality/survival
Primary endpoint: Success of the implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in cortical activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brown adipose tissue activation detection by Imaging using 18-FDG-PET/ MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy Expenditure using Whole Body Calorimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brown adipose tissue activation detection by Imaging using Infrared Thermography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of efficacy and safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Intervertebral motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Immune Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plantarflexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to Resolution of Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with storage symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Foveal Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability of the Arm, Shoulder and Hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of circulating blood fibrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Epicardial Fat Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Glucose Level Post-meal (AUC [0-4])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: subjective functional ankle recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of bcr-abl peptide vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: total exercise time on a treadmill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drain fluid content analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inferiority of High-dose Inactivated Influenza Vaccine
Endpoint domain: Mortality/survival
Primary endpoint: Emergency level agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of opioid negative urines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability assessment of serious adverse events (SAE) and adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Infectious Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Emotion Recognition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Theory of Mind (Eyes Test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: One-year Recurrence-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of headache and migraine
Endpoint domain: Adverse events/effects
Primary endpoint: Time to start of systemic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour levels of leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 hour levels of ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: circulating fibrocyte proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportional Change From Baseline in Auditory Hallucination Rating Scale (AHRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon dioxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of anxiety and depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Elimination of narcotic use post-operatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Apnea-hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in ten repetition maximum strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in isokinetic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change in Balance Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic enhancement of breast by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Daytime Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in average daily pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wearing-off symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Intraocular pressure without therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of skin blanching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of PAL hetero-VISA within MRSA isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and toxicity of Erbitux
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of child maltreatment protective factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in number and amount of income supports
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in social capital available to caregiver
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in parenting and child-rearing attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: measured glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intestinal microbiotic composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUCinf for EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf for LN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who are not smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Belimumab infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal diabetes self-care activities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Facial Palsy Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients experiencing adverse events or serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in primary serological bone biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to chemotherapy at treatment midpoint
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to chemotherapy at treatment endpoint
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pathological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGM Relative Differences to Laboratory Reference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intubation and mechanical ventilation in mild/moderate COVID-19 patients
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetic endpoints of THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic endpoints of 11-OH-THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic endpoints of CBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of psychosis
Endpoint domain: Adverse events/effects
Primary endpoint: Unscheduled Use of Healthcare
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence of hypermutable MRSA isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in clinical severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute rotavirus diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Pre-specified Safety Endpoints
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Absence of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events, especially infection and renal failure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in MELD Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Doctor evaluation of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Dyspepsia Related Health Scale (DRHS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute Change in FEV1 % Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of anal fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adoption of screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Provider adoption of CDS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Referral of high risk patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients With Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Effect on quality of life of implant loss
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Effect on body image of implant loss
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effect on depression and anxiety of implant loss
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Herpes Zoster
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ADHD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of nocturia frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep-Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Maximally tolerated doses (MTDs)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Cognitive development at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive development at 18 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive development at 60 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in postprandial glycaemia (2h plasma glucose level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in hepatic fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median biochemical progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life impact of treatments' side effects
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in Bone Mineral Density (BMD) in lumbar spine (L1-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage change in BMD in the femoral neck and total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Absolute change in BMD in the lumbar spine (L1-L4), femoral neck and total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional (dynamic) balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eventration
Endpoint domain: Adverse events/effects
Primary endpoint: Schirmer Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time-Curve From Time 0 to Infinity (AUC0-inf) of GDC-0853 Capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of GDC-0853 Capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of GDC-0853 Capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration at Steady State (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of prophylactic donor lymphocyte infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of administering prophylactic donor lymphocyte infusion
Endpoint domain: Resource use
Primary endpoint: Hip specific function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiation exposure as assessed by fluoroscopy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure as assessed by total emittance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving intervertebral fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone marrow adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pedicle screw instrumentation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in composition of the microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in concentration of pesticide residues in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Ovulation as determined by blood progesterone measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Significant Reduction in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical intra-epithelial neoplasia grade 2 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intrapatient variability of tacrolimus levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to end stage renal disease
Endpoint domain: Mortality/survival
Primary endpoint: Time to cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Moderate or severe COPD exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-Operative Pain Medication Usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of global inhomogeneity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength assessment (handgrip and limb muscle strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial Pulse Wave Velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in high sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase of HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase of paraoxonase 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-Abdominal Pressure (IAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of PX-478
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical responses (complete/partial/failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of PGP from sputum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Seroconverted Subjects for Serum H5N1 Haemagglutination-inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Were Seroprotected for Anti-HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chronic Left Ventricular Lead-related Complication Free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes